Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Oxaliplatin and Sorafenib Combination in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Relapsed After a Cisplatin Based Treatment

NCT01262482 is registered in ClinicalTrials.gov with Grupo Espanol Multidisciplinario del Cancer Digestivo as lead sponsor.

NCT NCT01262482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01262482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Oxaliplatin and Sorafenib Combination in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Relapsed After a Cisplatin Based Treatment
Lead sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
December 31, 2011
Enrollment
41 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (relapsed after a cisplatin based treatment)